Advertisement

Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects

Published on: 

Kausik Ray, MD, MBChB, MPhil, discusses the results from the phase 2 RESOLVE-1 trial, highlighting the investigational treatment’s effects on inflammatory biomarkers.

Inhibiting the NLRP3-IL-1β-IL-6-hsCRP cascade with ruvonoflast may successfully address residual inflammation through downstream effects, improving cardiovascular disease risk, according to the RESOLVE-1 study.1

These data were presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, Illinois, by Kausik Ray, MD, MBChB, MPhil, professor of public health at Imperial College London and director of the Imperial Centre for Cardiovascular Disease Prevention.1

“We’ve got very good animal data; we’ve got lots of tissue data that show that inflammation is relevant. The problem is that it’s really complicated, and there are multiple steps,” Ray told HCPLive in an exclusive interview. “There’s a cascade, and right at the top of that cascade is NLRP3 – if you hit that part, you’re hitting a number of other processes.”

RESOLVE-1 was a 24-week multicenter, randomized, double-blind, placebo-controlled phase 2 trial enrolling patients with a body mass index (BMI) ≥30 kg/m2 and <40 kg/m2, as well as a history of ≥1 self-reported unsuccessful dietary effort to lose body weight. Additionally, patients were split into 2 groups; the first of these was required to have a diagnosis of type 2 diabetes mellitus (T2DM), while the other was required to have none. Patients with type 1 diabetes, ≥1 episode of severe hypoglycemia 6 months prior, or a history of stroke, among other criteria, were excluded.2

Patients were randomly assigned in a 1:1:1 ratio to receive either ruvonoflast, an investigational oral small-molecule NLRP3 inflammasome inhibitor, at 150 mg/day or 300 mg/day, or placebo. The co-primary endpoints included the ratio of change in hsCRP in patients with obesity and without T2DM and the change in body weight with obesity with and without T2DM, both from baseline to week 24. Secondary outcomes included HbA1c at week 24 and incidence of body weight loss ≥5%, ≥10%, and ≥15% at week 24.2

Ray and colleagues enrolled 176 patients in the trial, assigning 59 to the 150 mg arm, 59 to the 300 mg arm, and 58 to placebo. Of these patients, 51% had T2DM, median hsCRP was 3.2 mg/L (interquartile range [IQR], 1.66 to 5.89), and mean age was 53.7 years (range, 21 to 75). By week 4, geometric least-squares mean hsCRP reductions were -38.1% in the 150 mg arm, -40.7% in the 300 mg arm, and 8% in the placebo arm. These effects were maintained up to week 24, wherein geometric least-squares mean hsCRP reductions were -25.7% with 150 mg, -25.9% with 300 mg, and 11.6% with placebo.1

In addition to hsCRP, interleukin-6 (IL-6) and fibrinogen were significantly reduced with ruvonoflast versus placebo. The magnitude of these effects was hsCRP >3 mg/L and adherent exposure. Adverse event frequencies were also comparable between the 3 arms, including infections. No treatment-related serious adverse events were reported during the study.1

Ultimately, Ray and colleagues determined that upstream inhibition of the NLRP3-IL-1β-IL-6-hsCRP axis through ruvonoflast treatment could potentially address residual inflammation via its broad downstream effects. A series of phase 3 trials, including doses ≤450 mg/day, is currently planned for early 2027. Ray also discussed his hopes for the upcoming trials, highlighting the need for further long-term safety data.1

“We want more safety data. This was 6 months of follow-up, but we’re clearly thinking about chronic, long-term dosing,” Ray said. “You want to know, over a year and a half, or whatever the follow-up will be in our next studies, whether these treatments are safe to use, and that’s the information we’re going to get.”

Editors’ Note: Ray reports disclosures with Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, Regeneron, and others.

References
  1. Butler J, Clarke N, Digby Z, et al. Anti-Inflammatory Efficacy and Safety of Oral NLRP3 Inhibitor Ruvonoflast: Results From the Phase 2 RESOLVE-1 Trial. Presented at the American Heart Association (AHA) Scientific Sessions 2026, Chicago, IL. November 6-9, 2026.
  2. NodThera Ltd. Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus (RESOLVE-1). ClinicalTrials.gov Identifier: NCT07055516. Updated September 15, 2026. Accessed November 19, 2026. https://clinicaltrials.gov/study/NCT07055516?term=NCT07055516&rank=1

Advertisement
Advertisement